EMIT II Plus Benzodiazepine Assay

Screen for benzodiazepines and benzodiazepine metabolites

The EMIT® II Plus Benzodiazepine Assay is intended for the qualitative and semiquantitative analysis of benzodiazepine and benzodiazepine metabolites in human urine at a cutoff value of 200 ng/mL or 300 ng/mL.

Contact Us

Features & Benefits

Benzodiazepines are sedative-hypnotic drugs that are structurally similar and include widely used drugs such as chlordiazepoxide, diazepam, and oxazepam. The different benzodiazepines are absorbed at different rates, and the timing of their psychoactive effects varies with the absorption rate.

The EMIT II Plus Benzodiazepine Assay provides:

  • Excellent precision—all within-lab (total) CVs ≤1.0% or less across the assay range
  • Dual cutoffs available with one assay
  • Ready-to-use liquid reagents, calibrators, and controls
  • >80% correlation to the reference method

 

Applications are available for the Viva-Jr®, Viva-E®, Viva-ProE®, V-Twin® drug testing systems and AU® Series analyzers.

Technical Specifications

 Assay Principle

  Homogeneous Enzyme Multiplied Immonoassay (EMIT)

 Cut-off

  200 ng/mL and 300 ng/mL

 Sample

  Urine  

 Reagent Stability

  Unopened until expiration date; Onboard instrument: up to 4 weeks

 Calibration Frequency

  As indicated by control results